Ind-Swift Laboratories Limited Bombay S.E.

INDSWFTLAB

INE915B01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-18 am EDT			5-day change	1st Jan Change
116.5 ^INR	-3.74%		-10.20%	+12.08%

Mar. 18	Ind-Swift Laboratories Limited Announces Cessation of Sunil Deshmukh as Chief Executive Officer	CI
Mar. 18	Ind-Swift Laboratories Limited Announces Cessation of Lovekesh Mahajan as Chief Accounts Officer	CI

Ind-Swift Laboratories Limited Appoints Mr. Sunil Deshmukh as Key Managerial Personnel

April 01, 2021 at 09:40 am EDT

Ind-Swift Laboratories Limited announced that Mr. Sunil Deshmukh has been appointed as Key Managerial Personnel of the Company, with effect from April 01, 2021.

Latest news about Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited Announces Cessation of Sunil Deshmukh as Chief Executive Officer	Mar. 18	CI
Ind-Swift Laboratories Limited Announces Cessation of Lovekesh Mahajan as Chief Accounts Officer	Mar. 18	CI
Ind-Swift Laboratories Limited Redeems in Full, the 4245 Rated, Listed, Secured, 10% Coupon, Redeemable, Non-Convertible Debenture	Mar. 18	CI
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited and Essix Biosciences Limited.	Mar. 17	CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
CARE Keeps BB Rating on Ind-Swift Laboratories' Long-term Financing; Rating Under Watch Developing	Dec. 20	MT
Ind-Swift Laboratories Limited Collaborates with The Council of Scientific and Industrial Research	Nov. 29	CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 07	CI
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited.	23-09-24	CI
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories	23-09-06	MT
India's Ind-Swift Labs to sell pharma ingredients ops for $198.5 million	23-09-06	RE
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.	23-09-05	CI
Ind-Swift Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-09	CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
RN Chemicals & Pharmaceutical Private Limited acquired Halcyon life Sciences Private Limited from Ind-Swift Laboratories Limited for INR 5 million.	23-03-29	CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI

Chart Ind-Swift Laboratories Limited

Duration

Period

More charts

Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing intermediates and formulations. The Companyâs products or services include Advanced Intermediates. It is API partner for many organizations both in generic and innovative domains. The Company offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.40%	44.1B
OTSUKA HOLDINGS CO., LTD.	+17.11%	21.97B
CIPLA LIMITED	+8.10%	13.27B
SANDOZ GROUP AG	+6.69%	13.22B
ZYDUS LIFESCIENCES LIMITED	+35.95%	11.36B
ONO PHARMACEUTICAL CO., LTD.	-8.53%	7.07B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.09%	5.23B